Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylephrine + heparin is a combination of two active pharmaceutical ingredients used together, typically in hospital or procedural settings. Phenylephrine is an alpha-1 adrenergic receptor agonist that acts as a vasoconstrictor, increasing blood pressure and reducing swelling by constricting blood vessels[3][8]. Heparin is an anticoagulant that prevents the formation and extension of blood clots by potentiating the activity of antithrombin III, thereby inhibiting thrombin and factor Xa[6]. This combination may be used in clinical scenarios where both vasoconstriction (to maintain vascular tone or reduce local bleeding) and anticoagulation (to prevent catheter-related thrombosis or maintain line patency) are desired. There are no widely recognized brand names for this specific combination; it may be prepared for specific procedural use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylephrine + heparin.